Wilson Sonsini Goodrich & Rosati along with Latham & Walkins have advised Avidity Biosciences. Avidity Biosciences, Inc., a biopharmaceutical company listed on Nasdaq under the symbol...
Avidity Biosciences Prices $600 Million Upsized Public Offering of Common Stock
CRISPR Therapeutics’ Multi-Target Collaboration with Sirius Therapeutics
Wilson Sonsini Goodrich & Rosati advised Sirius on patent matters related to the transaction. CRISPR Therapeutics (NASDAQ: CRSP), a biopharmaceutical company focused on creating transformative gene-based...
Verdiva Bio’s $410 Million Series A Financing Round
Wilson Sonsini Goodrich & Rosati advised General Atlantic on IP matters related to the transaction. Verdiva Bio Limited announced its launch as a clinical-stage biopharmaceutical company...
Avidity Biosciences’ $300 Million Common Stock Offering
Latham & Watkins advised Avidity Biosciences on the deal, and Wilson Sonsini Goodrich & Rosati acted as patent counsel to Avidity. Avidity Biosciences, Inc. (Nasdaq: RNA),...
Avidity Biosciences’ $461 Million Common Stock Offering
Latham & Watkins advised Avidity Biosciences, Inc. on the offering, and Wilson Sonsini Goodrich & Rosati advised Avidity on patent matters related to the transaction. Cooley...
Genmab’s $1.8 Billion Acquisition of ProfoundBio
Cooley, Travers Thorp Alberga and Jun He Law Offices advised ProfoundBio and Wilson Sonsini Goodrich and Rosati advised ProfoundBio on patent matters related to the transaction,...
Avidity Biosciences’ $400 Million Shares Private Placement
Wilson Sonsini Goodrich & Rosati advised Avidity on patent matters related to the transaction. Avidity Biosciences, Inc. (Nasdaq: RNA) announced that it has agreed to sell 15,224,773...
JIXING’s Collaborations with TMS
Wilson Sonsini Goodrich & Rosati advised Ji Xing Pharmaceuticals Limited (JIXING) on the transaction. TMS Co., Ltd. (TMS) and Ji Xing Pharmaceuticals Limited (JIXING) announced that...